Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials
Time: 11:00 am
day: Conference Day One - Track B - AM
Details:
Unique translational science platform enables us to track the active component of TIL (clonal neoantigen reactive T-cell) in patients and determine key mechanisms underpinning in vivo activity
Key insights to date include:
- Impact of host conditioning in T-cell persistence and engraftment
- Critical role of evasion mechanisms (such as HLA loss) in resistance to T-cell based therapies
